Medicus Pharma Launches Phase 2 Clinical Study in UAE for Skin Cancer Treatment

Medicus Pharma Ltd. has begun treating its first patient in a phase 2 clinical study aimed at treating basal cell carcinoma (BCC) non-invasively in the United Arab Emirates (UAE). The study, known as SKNJCT-004, involves 36 participants across six medical sites including the Cleveland Clinic Abu Dhabi.

A UAE-based research organization, Insights Research Organization and Solutions (IROS), is managing the study, which evaluates the efficacy of different doses of D-MNA, a dissolvable microneedle array containing doxorubicin. This initiative reflects Medicus's strategy to expand beyond the United States, tapping into a global market opportunity worth over $2 billion in non-melanoma skin disease treatments.

The study structure is a placebo-controlled, double-blind trial involving three groups to assess D-MNA's effectiveness compared to placebo. The high-dose of 200μg used in this phase follows successful safety trials completed in 2021.